Skip to main content
. Author manuscript; available in PMC: 2022 Dec 16.
Published in final edited form as: Clin Cancer Res. 2022 May 13;28(10):2180–2195. doi: 10.1158/1078-0432.CCR-21-0833

Figure 4.

Figure 4.

Inhibition of mitochondrial respiration by Gamitrinib in gliomas. A and B, Mitochondrial respirations of LN229 (A) and M059K (B) cells treated with DMSO, IACS-010759, Phenformin, Gboxin, and Gamitrinib, respectively, were measured by a Seahorse XF96 Analyzer. Data were representative of 4 to 5 biological replicates. C and D, Mitochondrial respirations of LN229 (C) and M059K (D) cells treated with DMSO, Gamitrinib 1 μmol/L, Gamitrinib 2.5 μmol/L, and Gamitrinib 5 μmol/L, respectively, were measured by a Seahorse XF96 Analyzer. Data were representative of 4 to 5 biological replicates. E, Mitochondrial respirations of LN229 cells treated with DMSO, Gamitrinib, TMZ or Gamitrinib plus TMZ, respectively, were measured by a Seahorse XF96 Analyzer. Data were representative of 4 to 5 biological replicates. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.